An intravenous antibody–drug conjugate (ADC) dosed every 3 weeks. A monoclonal antibody binds a tumor-associated surface antigen on solid tumors, is internalized, and releases a cytotoxic payload to kill antigen-positive cells. Based on protocol exclusions, it likely targets B7‑H3 (CD276) and may use a topoisomerase I inhibitor payload (not explicitly confirmed).
Intravenous ADC in which a monoclonal antibody binds a tumor‑associated surface antigen on solid tumors (protocol suggests B7‑H3/CD276), is internalized, and releases a cytotoxic payload—likely a topoisomerase I inhibitor—to induce DNA damage and kill antigen‑positive tumor cells.
YES
DIRECT
ADC binds B7-H3 on target cells, is internalized, and releases a cytotoxic (likely topoisomerase I inhibitor) payload that induces DNA damage leading to cell death.
Autologous T cells engineered with a retroviral vector to express a single bispecific chimeric antigen receptor targeting CD19 and CD22, enabling TCR-independent activation, expansion, cytokine release, and cytotoxic killing of B-lineage leukemia; used to eradicate MRD and induce B-cell aplasia.
Autologous T cells are retrovirally engineered to express a single tandem (bispecific) CAR that recognizes CD19 and CD22 on B-lineage cells. Antigen binding triggers TCR-independent CD3ζ/costimulatory signaling, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19+/CD22+ leukemia, resulting in MRD clearance and B-cell aplasia.
YES
DIRECT
Bispecific CAR-T cells bind CD22 on target cells, triggering CD3ζ/costimulatory signaling and immune synapse formation, leading to perforin/granzyme-mediated lysis (and death-receptor apoptosis).
An intravenous antibody–drug conjugate (ADC) dosed every 3 weeks. A monoclonal antibody binds a tumor-associated surface antigen on solid tumors, is internalized, and releases a cytotoxic payload to kill antigen-positive cells. Based on protocol exclusions, it likely targets B7‑H3 (CD276) and may use a topoisomerase I inhibitor payload (not explicitly confirmed).
Intravenous ADC in which a monoclonal antibody binds a tumor‑associated surface antigen on solid tumors (protocol suggests B7‑H3/CD276), is internalized, and releases a cytotoxic payload—likely a topoisomerase I inhibitor—to induce DNA damage and kill antigen‑positive tumor cells.
NO
INDIRECT
7MW3711 is an ADC that binds a surface antigen (likely B7-H3/CD276), is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage. Killing depends on the surface antigen, not on topoisomerase I expression itself.
Human IgG1k monoclonal antibody targeting CD38; mediates ADCC, CDC, and ADCP and is used to treat multiple myeloma.
Human IgG1k monoclonal antibody targeting CD38; binds CD38 on myeloma and immune cells and induces cell death via Fc-mediated effector functions (ADCC, CDC, ADCP). Depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs) and can inhibit CD38 ectoenzyme activity, promoting antitumor immunity.
YES
DIRECT
Anti-CD38 antibody binds CD38 on target cells and recruits immune effectors via its Fc to induce ADCC and ADCP; it also activates complement (CDC). May also trigger apoptosis upon binding/crosslinking.
BCMA x CD3 bispecific IgG4 antibody that redirects T cells to kill BCMA-expressing myeloma cells.
Humanized bispecific IgG4 antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells to BCMA+ myeloma cells to activate cytotoxic T-cell responses and induce targeted tumor cell killing.
YES
DIRECT
Teclistamab bridges CD3 on T cells to BCMA on target cells, activating T cells to form cytolytic synapses and kill BCMA+ cells via perforin/granzyme-mediated apoptosis.